

Hikma Launches Basilea's Antibiotic 'Ceftobiprole' in Saudi Arabia

Amman, Jordan, May 15, 2018 – [Hikma Pharmaceuticals LLC](#), in partnership with Basilea Pharmaceutica Ltd., announced today the launch of Basilea's hospital antibiotic 'Ceftobiprole' in Saudi Arabia.

Adesh Kaul, Basilea Chief Corporate Development Officer, said, "We are very pleased with the launch of Ceftobiprole in Saudi Arabia. This is the first launch by our partner **Hikma**, a leading pharmaceutical company in the Middle East and North Africa region. Infections with bacteria resistant to established antibiotics remain a major health care concern across this region. Following the market entry in Saudi Arabia we are therefore looking forward to **Hikma** expanding the availability of Ceftobiprole to further countries in the Middle East and North Africa."

Mazen Darwazah, **Hikma** Executive Vice Chairman, President and CEO of MENA and Emerging Markets, said, "We are glad to be building on our partnership with Basilea to bring important medicines to the Saudi Market in particular and the MENA region in general. By working with global partners like Basilea we are reinforcing our commitment to providing better health to more people every day."

Ceftobiprole is approved in Saudi Arabia for the treatment of adult patients with hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP), and for the treatment of community-acquired pneumonia (CAP).¹

Basilea entered into a Distribution and License Agreement for Ceftobiprole with **Hikma** in 2015 and for the antifungal Isavuconazole in 2016.

-- ENDS --

About Hikma

Hikma puts better health, within reach, every day, for millions of people in more than 50 countries around the world. For 40 years, we have been creating high-quality medicines, and making them accessible and affordable to the people who need them. We are a global company with a local presence across the United States (U.S.), the Middle East and North Africa (MENA), and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We are committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner in the MENA region, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit www.hikma.com, or contact:

Hana Darwazeh Ramadan
Email: Media@Hikma.com
Tel: +962 6 580 2900

¹ U.K. Summary of Product Characteristics (SPC) Ceftobiprole: <http://www.mhra.gov.uk/>
[Accessed: April XX, 2018]

About Basilea

Basilea Pharmaceutica Ltd. is a commercial stage biopharmaceutical company developing products that address the medical challenge of increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. With two commercialized drugs, the company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website www.basilea.com.